ONCOLOGY / BASIC RESEARCH
3-Acetyl-11-keto-β-boswellic acid inhibits cancer cell invasion and induces apoptosis in breast cancer cells by abrogating the EGFR-mediated PI3K/Akt pathway
More details
Hide details
1
Department of Breast Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Dadong District, Shenyang, Liaoning, China
Submission date: 2020-01-04
Final revision date: 2020-03-17
Acceptance date: 2020-04-01
Online publication date: 2020-05-18
Publication date: 2026-01-16
Corresponding author
Hong Xu
Department of
Breast Cancer
Cancer Hospital of
China Medical University
Liaoning Cancer Hospital
and Institute
44 Xiaoheyan Road
Dadong District
Shenyang
Liaoning 110042, China
Arch Med Sci 2025;21(6):2522-2536
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Recent evidence has demonstrated the anticancer potential of 3-acetyl-11-keto--boswellic acid (AKBA). The current study was performed to evaluate the anti-invasive and antimotility effect of AKBA against breast cancer (BC) cells.
Material and methods:
The antiproliferative assay was used to evaluate cell viability. Wound healing assay and Transwell invasion assay were used for migration and invasion respectively. Annexin V FITC assay and microscopy were used to quantify and detect apoptosis. Zymography and immunoblotting analysis were used for gelatinase activity of matrix metalloproteinases (MMPs) and protein expression of signaling proteins involved in apoptosis, tumor cell invasion and motility of BC cells.
Results:
AKBA exhibits significant inhibition of cell proliferation and suppresses BC cell motility. Mechanistically, AKBA suppresses migration and invasion, and attenuates MMP-2 and MMP-9 activity, which plays a key role in metastasis. Furthermore, a dose-dependent manner of AKBA promotes significant induction of apoptosis. Moreover, we observed that a higher concentration of AKBA reduces phosphorylation of EGFR, PI3K, and Akt with a subsequent decrease in MMP-9 and MMP-2 expression, and an increase in TIMP1 and E-cadherin expression. However, pre-treatment with EGF in BC cells restores significant cell motility and invasion even in the presence of AKBA, indicating that inhibition of cell migration by AKBA is operated by the EGFR/PI3K/Akt axis. Additionally, AKBA showed a significant inhibitory and strong synergistic effect on EGFR-mediated PI3K/Akt signaling associated proteins when compared with the known inhibitors gefitinib and erlotinib.
Conclusions:
AKBA exhibits potential antiproliferative effects by inducing apoptosis and suppresses tumor cell motility and invasion, which is mediated by the EGFR/PI3K/Akt axis in BC cells
REFERENCES (43)
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2.
Ruiz R, Herrero C, Strasser-Weippl K, et al. Epidemiology and pathophysiology of pregnancy-associated breast cancer: a review. Breast 2017; 35: 136-41.
3.
Koczkodaj P, Sulkowska U, Gotlib J, Mańczuk M. Breast cancer mortality trends in Europe among women in perimenopausal and postmenopausal age (45+). Arch Med Sci 2020; 16: 146-56.
4.
Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 2010; 19: 27-32.
5.
Ying C, Wang S, Lu Y, et al. Glucose fluctuation increased mesangial cell apoptosis related to AKT signal pathway. Arch Med Sci 2019; 15: 730-7.
6.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Rev Clin Oncol 2016; 13: 674-90.
7.
Momtazi-Borojeni AA, Nik ME, Jaafari MR, Banach M, Sahebkar A. Effects of immunization against PCSK9 in an experimental model of breast cancer. Arch Med Sci 2019; 15: 570-9.
8.
Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009; 18: 125-32.
9.
Spanheimer PM, Cyr AR, Gillum MP, Woodfield GW, Askeland RW, Weigel RJ. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy. Ann Surg 2014; 259: 793-9.
10.
Subik K, Lee JF, Baxter L, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 2010; 4: 35-41.
11.
Soysal SD, Muenst S, Barbie T, et al. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer 2013; 108: 1480-7.
12.
Rethemiotaki I, Rethemiotakis A. Stroke and breast cancer in the United States during 2007–2017. Arch Med Sci Atheroscler Dis 2019; 4: e134-40.
13.
Lee KW, Bode AM, Dong Z. Molecular targets of phytochemicals for cancer prevention. Nature Rev Cancer 2011; 11: 211-8.
14.
Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res 2015; 35: 645-51.
15.
Whitlock NC, Baek SJ. The anticancer effects of resveratrol: modulation of transcription factors. Nutrition Cancer 2012; 64: 493-502.
16.
Rah B, Rasool Ru, Nayak D, et al. PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. Autophagy 2015; 11: 314-31.
17.
Eken MK, Ersoy GS, Kaygusuz EI, et al. Etanercept protects ovarian reserve against ischemia/reperfusion injury in a rat model. Arch Med Sci 2019; 15: 1104-12.
18.
Guo H, He Y, Bu C, Peng Z. Antitumor and apoptotic effects of 5-methoxypsoralen in U87MG human glioma cells and its effect on cell cycle, autophagy and PI3K/Akt signaling pathway. Arch Med Sci 2019; 15: 1530-8.
19.
Thaiparambil JT, Bender L, Ganesh T, et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer 2011; 129: 2744-55.
20.
Sabina EP, Indu H, Rasool M. Efficacy of boswellic acid on lysosomal acid hydrolases, lipid peroxidation and anti-oxidant status in gouty arthritic mice. Asian Pac J Trop Biomed 2012; 2: 128-33.
21.
Siddiqui M. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharmaceut Sci 2011; 73: 255-61.
22.
Park B, Sung B, Yadav VR, Cho SG, Liu M, Aggarwal BB. Acetyl-11-keto-beta-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. Int J Cancer 2011; 129: 23-33.
23.
Shen Y, Takahashi M, Byun HM, et al. Boswellic acid induces epigenetic alterations by modulating DNA methylation in colorectal cancer cells. Cancer Biol Ther 2012; 13: 542-52.
24.
Glaser T, Winter S, Groscurth P, et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 1999; 80: 756-65.
25.
Zhao W, Entschladen F, Liu H, et al. Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev 2003; 27: 67-75.
26.
Banno N, Akihisa T, Yasukawa K, et al. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 2006; 107: 249-53.
27.
Rah B, Amin H, Yousuf K, et al. A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PLoS One 2012; 7: e44039.
28.
Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon H. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992; 261: 1143-6.
29.
Safayhi H, Sailer ER, Ammon H. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol 1995; 47: 1212-6.
30.
Bishayee A, Ahmed S, Brankov N, Perloff M. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 2011; 16: 980-96.
31.
Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem 2006; 13: 3359-69.
32.
Takahashi M, Sung B, Shen Y, et al. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis 2012; 33: 2441-9.
33.
Li W, Liu J, Fu W, et al. 3-O-acetyl-11-keto-beta-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. J Exp Clin Cancer Res 2018; 37: 132.
34.
Patridge E, Gareiss P, Kinch MS, Hoyer D. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today 2016; 21: 204-7.
35.
Ding Y, Chen M, Wang M, et al. Neuroprotection by acetyl-11-keto-beta-boswellic acid, in ischemic brain injury involves the Nrf2/HO-1 defense pathway. Sci Rep 2014; 4: 7002.
36.
Hartmann RM, Martins MIM, Tieppo J, Fillmann HS, Marroni NP. Effect of Boswellia serrata on antioxidant status in an experimental model of colitis rats induced by acetic acid. Dig Dis Sci 2012; 57: 2038-44.
37.
Singh S, Khajuria A, Taneja S, Johri R, Singh J, Qazi G. Boswellic acids: a leukotriene inhibitor also effective through topical application in inflammatory disorders. Phytomedicine 2008; 15: 400-7.
38.
Parr C, Ali AY. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling. J Transl Med 2018; 16: 281.
39.
Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 1993; 9: 541-73.
40.
Taraphdar AK, Roy M, Bhattacharya R. Natural products as inducers of apoptosis: implication for cancer therapy and prevention. Curr Sci 2001; 80: 1387-96.
41.
Roy NK, Deka A, Bordoloi D, et al. The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett 2016; 377: 74-86.
42.
Shukla S, MacLennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121: 1424-32.
43.
Singh I, Amin H, Rah B, Goswami A. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer. Front Biosci (Schol Ed) 2013; 5: 231-46.